Trending: Eli Lilly's Alzheimer's Treatment Gets FDA Advisory Panel Backing
Provided by
Dow Jones
09:37 ET -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Advisers to the Food and Drug Administration said the benefits of Lilly's Alzheimer's treatment, donanemab, outweigh the risks for most patients. All 11 members of the Peripheral and Central Nervous System Drugs Advisory Committee voted that evidence supports the effectiveness of donanemab for patients with Alzheimer's disease. Shares are up 2.5%. Dow Jones & Co. owns Factiva. (zaeem.shoaib@wsj.com)
(END) Dow Jones Newswires
June 11, 2024 09:52 ET (13:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations